This is the 1st CCSG competitive renewal of the Dan L. Duncan Cancer Center (DLDCC) at Baylor College of Medicine (BCM) in Houston. BCM is located in the Texas Medical Center (TMC), the largest medical center in the country, and Houston is the 4th largest city with a very diverse population. The DLDCC is a matrix Cancer Center with BCM as the lead scientific partner with three hospital affiliates, Texas Children's, the DeBakey Veterans Affairs Medical Center, and Ben Taub General Hospital, as formal clinical partners. The Center was established in 2002 and received NCI designation in July of 2007 and has since made significant progress strengthening its scientific research programs, taking into consideration the prior review and recommendations from our EAB. 37 new cancer faculty have been recruited to the DLDCC which now has 350 formal members, and our cancer-relevant peer reviewed research funding now exceeds $122 million (22% increase), with more than $36 million coming from the NCI. Several high-impact research accomplishments have been made by members, several with the potential to reduce cancer mortality. The DLDCC comprises 7 research programs: Cancer Biology, Viral and Molecular Oncogenesis, Nuclear Receptors, Breast Cancer, Cancer Cell and Gene Therapy, Cancer Prevention and Population Science, and Pediatric Cancer. Investments exceeding $10 million have strengthened the scientific resources, which offer leading technologies and expertise to members. CTSU has been significantly enhanced and accruals to clinical trials have increased over 40%. Accrual of racial and ethnic minorities continues to be outstanding. The Office of Outreach and Health Disparities, using tools developed from NCI funding, disseminates new information to the community, especially the underserved. In this renewal, we ask for increased funding for our 10 Shared Resources, 3 developing resources, and other activities important to our mission and goals, as well as consideration for comprehensive designation according to NCI guidelines.

Public Health Relevance

The investments made by the NCI, combined with the support of the Houston community and the hard work of exceptional scientists, clinicians and staff of the Dan L. Duncan Cancer Center has created a strong center that is increasing our knowledge and understanding of cancer biology and delivering care to a broad spectrum of patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA125123-04
Application #
7944476
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
2007-07-01
Project End
2015-06-30
Budget Start
2010-09-17
Budget End
2011-06-30
Support Year
4
Fiscal Year
2010
Total Cost
$3,089,219
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Gibbons, Don L; Creighton, Chad J (2018) Pan-cancer survey of epithelial-mesenchymal transition markers across the Cancer Genome Atlas. Dev Dyn 247:555-564
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
McClard, Cynthia K; Kochukov, Mikhail Y; Herman, Isabella et al. (2018) POU6f1 Mediates Neuropeptide-Dependent Plasticity in the Adult Brain. J Neurosci 38:1443-1461
Hogstad, Brandon; Berres, Marie-Luise; Chakraborty, Rikhia et al. (2018) RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions. J Exp Med 215:319-336
Amirian, E Susan; Ostrom, Quinn T; Armstrong, Georgina N et al. (2018) Aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-Analysis. Cancer Epidemiol Biomarkers Prev :
Mishra, Prachi; Tang, Wei; Putluri, Vasanta et al. (2018) ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming. J Clin Invest 128:323-340
Piyarathna, Danthasinghe Waduge Badrajee; Rajendiran, Thekkelnaycke M; Putluri, Vasanta et al. (2018) Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder. Eur Urol Focus 4:907-915
Criglar, Jeanette M; Anish, Ramakrishnan; Hu, Liya et al. (2018) Phosphorylation cascade regulates the formation and maturation of rotaviral replication factories. Proc Natl Acad Sci U S A 115:E12015-E12023
Rimawi, Mothaffar F; De Angelis, Carmine; Contreras, Alejandro et al. (2018) Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat 167:731-740
Ostrom, Quinn T; Kinnersley, Ben; Armstrong, Georgina et al. (2018) Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. Int J Cancer 143:2359-2366

Showing the most recent 10 out of 991 publications